MapLight Therapeutics, Inc. (MPLT): Total Assets
$479.51M
As of 2025-12-31
$368.35M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $479.51M | +250.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $136.92M | n/a | 2026-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | $479.51M | +250.2% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $480.20M | +22.4% |
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | $476.17M | +46.2% |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $485.57M | +37.1% |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | $488.62M | +23.4% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $488.95M | -25.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $501.60M | +15.1% |
| Biohaven Ltd. (BHVN) | 2025-12-31 | $451.45M | -26.6% |
| Rapport Therapeutics, Inc. (RAPP) | 2025-12-31 | $512.43M | +62.7% |
Compare MPLT, RYTM, ELVN, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗